Ferrante Karen Jean
Transaction: 07/01/2026
BUY
Change
+627
Price
$38.48
Filing
07/06/2026
Type
BUY
Cogent Biosciences, Inc.
COGT • Biotechnology
$34.76
▼ -0.19 (-0.54%)
Current price
EarningsLatest report: Jun 30, 2026
HIGHER-RISK PROFILECautionConfidence: 70%
Quantitative profile — not an investment recommendation.
Quantitative profile — not an investment recommendation.Methodology
Analysis thesis: Caution is warranted. Recent ratios show weaknesses that may limit returns unless fundamentals improve.
Market Cap
$1.37B
Growth
-100.0%
Cash Flow
0/5
Trend
Negative
Evidence
Manageable debt level · 0.4Healthy liquidity · 14.23Weak profitability
Financial data as of: Jun 30, 2026, 12:00 AM UTCLast earnings update: Jun 30, 2026, 12:00 AM UTCLast profile update: Aug 12, 2026, 12:08 PM UTC
Company Snapshot
Key valuation, quality, financial strength, momentum and analyst data.
Price$34.76
Change-0.54%
Shares Out39.41M
Market Cap$1.37B
Enterprise Value$821.99M
52W Range10.98 - 43.73
Beta0.34
P/E-3.63
P/B2.57
P/FCF-4.43
EV/EBITDA-2.09
EV/FCF-2.66
Price$34.76
Change-0.54%
Shares Out39.41M
Market Cap$1.37B
Enterprise Value$821.99M
52W Range10.98 - 43.73
Beta0.34
P/E-3.63
P/B2.57
P/FCF-4.43
EV/EBITDA-2.09
EV/FCF-2.66
Earnings Yield-27.53%
FCF Yield-22.57%
Dividend Yield0.00%
Gross Margin0.00%
Oper. Margin0.00%
Profit Margin0.00%
Debt/Eq0.40
Current Ratio14.23
Quick Ratio14.23
Revenue 5Y-100.00%
Target$51.75
Target Upside48.88%
Target Median$53.50
Target Range45.00 - 55.00
Volume2.75M
Avg Volume2.36M
EPS Surprise0.00
Investment DNA
How strong this company looks for long-term investors
43
out of 100
Business Quality
Margins, moat, returns
22/100
Financial Strength
Debt, cash, stability
75/100
Growth Potential
Revenue and expansion
50/100
Price Attractiveness
Cheap or expensive today
72/100
Why this score▼
Manageable debt level · 0.4Healthy liquidity · 14.23Weak profitability
Analyst view
Analyst sentiment and price target
Analyst sentiment
Based on 12 analyst votes · 2026-09-05
92/100
Bullish
Bullish
10
Hold
2
Bearish
0
Price Target
2026-08-12
Low
$35.00
Mean
$46.75
Median
$48.50
High
$55.00
Insider Transactions
Recent executive and insider activity
⚠ 2 high-volume insider sells detected
Ros Matthew
Transaction: 06/09/2026
BUY
Change
+17,901
Price
$31.98
Filing
06/11/2026
Type
BUY
Morris Arlene
Transaction: 06/09/2026
BUY
Change
+17,901
Price
$31.98
Filing
06/11/2026
Type
BUY
| Insider | Type | Change | Price | Transaction | Filing |
|---|---|---|---|---|---|
| Ferrante Karen Jean | BUY | +627 | $38.48 | 07/01/2026 | 07/06/2026 |
| Ros Matthew | BUY | +17,901 | $31.98 | 06/09/2026 | 06/11/2026 |
| Morris Arlene | BUY | +17,901 | $31.98 | 06/09/2026 | 06/11/2026 |
| Shegog Todd | BUY | +17,901 | $31.98 | 06/09/2026 | 06/11/2026 |
| CAIN CHRISTOPHER W. | BUY | +17,901 | $31.98 | 06/09/2026 | 06/11/2026 |
| Ferrante Karen Jean | BUY | +17,901 | $31.98 | 06/09/2026 | 06/11/2026 |
| Harwin Peter Evan | BUY | +17,901 | $31.98 | 06/09/2026 | 06/11/2026 |
| Robbins Andrew R | BUY | +160,000 | Not reported | 05/19/2026 | 05/21/2026 |
| Ferrante Karen Jean | BUY | +686 | $35.24 | 04/01/2026 | 04/03/2026 |
| Fairmount Funds Management LLC | SELL | -28,000 | Not reported | 03/31/2026 | 03/31/2026 |
| Fairmount Funds Management LLC | SELL | -7,000,000 | $34.66 | 03/31/2026 | 03/31/2026 |
| Fairmount Funds Management LLC | SELL | -3,500,000 | $36.40 | 01/22/2026 | 01/22/2026 |
| Ferrante Karen Jean | BUY | +643 | $34.74 | 01/01/2026 | 01/05/2026 |
| Robinson John Edward | SELL | -90,000 | $38.74 | 12/26/2025 | 12/30/2025 |
| Sachs Jessica | SELL | -82,642 | $38.70 | 12/26/2025 | 12/30/2025 |
| Green John L. | SELL | -77,000 | $38.68 | 12/26/2025 | 12/30/2025 |
| Kearns Evan | SELL | -65,000 | $38.70 | 12/26/2025 | 12/30/2025 |
| Green John L. | BUY | +65,000 | $39.45 | 12/17/2025 | 12/19/2025 |
| Green John L. | BUY | +50,000 | Not reported | 12/17/2025 | 12/19/2025 |
| Sachs Jessica | BUY | +65,000 | $39.45 | 12/17/2025 | 12/19/2025 |